Sector News

Sunshine Act payment data leaves out newly influential prescribers

July 8, 2015
Life sciences
The Physician Payments Sunshine Act was meant to shine a light on pharma’s payments to doctors, boosting transparency and potentially reducing unsavory business practices. But the act leaves out a big chunk of prescribers: nurse practitioners and physician assistants (PAs).
 
As NPR reports, nurse practitioners and PAs play an increasingly large role in healthcare, taking on many of the same tasks as doctors. PAs and nurses wrote about 10% of the nearly 1.4 billion prescriptions in Medicare’s prescription drug program in 2013, according to a ProPublica analysis cited by NPR. The two groups wrote 15% of all scripts nationwide during the first 5 months of the same year, an IMS Health study notes.
 
While pharma’s relationships with doctors have historically drawn the most attention, nurses’ interactions with the industry have “as much relevance,” Dr. Walid Gellad, co-director of the University of Pittsburgh’s Center for Pharmaceutical Policy and Prescribing, told the news outlet. “If the purpose of the act is to shine a light on the relationship between industry and the healthcare sector, then you’ve left out an important component of that sector,” he said.
 
When the Sunshine Act was drafted, nursing groups weren’t covered by the law and thus weren’t a part of policy discussions, Allan Coukell, senior director for health programs at the Pew Charitable Trusts, told NPR. But just because that’s how the system worked in the past doesn’t mean it should continue in the same vein, he added.
 
“(T)o the extent that a lot of prescribing now is done by health professionals who aren’t physicians, and a lot of marketing is directed at them, they ideally should also be part of the disclosure,” Coukell said (as quoted by NPR).
 
Meanwhile, the industry has slowly begun to change its tune when it comes to interactions with healthcare providers. In 2013, GlaxoSmithKline CEO Andrew Witty pledged to end doctor payments by 2016 to give the company’s image a much-needed boost. While the company has yet to make big moves in that department, GSK plans to roll out a new suite of services by 2016 to replace paid speakers, loosening its ties with doctors. “We expect overall payments to continue decreasing as we continue to implement our new approach to working with healthcare professionals,” company spokeswoman Sarah Alspach told Bloomberg last month.
 
By Emily Wasserman
 

comments closed

Related News

May 4, 2024

Novartis acquires Mariana in $1.75bn deal to strengthen radioligand portfolio

Life sciences

Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.

May 4, 2024

Novo Nordisk aims for market domination, boasts $1.5bn obesity sales in Q1

Life sciences

The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.

May 4, 2024

Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn

Life sciences

Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.

How can we help you?

We're easy to reach